Hydroxyurea is associated with later onset of acute splenic sequestration crisis in sickle cell disease: Lessons from the European Sickle Cell Disease Cohort-Hydroxyurea (ESCORT-HU) study.
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
revised:
22
12
2023
received:
05
11
2023
accepted:
01
01
2024
pubmed:
22
1
2024
medline:
22
1
2024
entrez:
22
1
2024
Statut:
ppublish
Résumé
Acute splenic sequestration crisis (ASSC) is a potentially life-threatening complication of sickle cell disease (SCD), typically occurring in young patients under 5 years of age, with a median age at first episode of less than 2 years. Because a beneficial effect of hydroxyurea (HU) on spleen perfusion and splenic function has been suspected, we hypothesized that HU treatment might be associated with later onset of ASSC in patients with SCD. To investigate this hypothesis, we analyzed data from the ESCORT-HU study on a large cohort of patients with SCD receiving HU, enrolled between January 2009 and June 2017 with a follow-up of 7309 patient-years of observation. The median age at ASSC of the 14 patients who experienced a first episode of ASSC during the study period was 8.0 [IQR: 5.0-24.1] years. The median age at HU initiation was significantly lower in these 14 patients (4.8 [IQR: 3.3-18.7] years) compared to the 1664 patients without ASSC (19.9 [8.8-33.4] years, p = .0008). These findings suggest that ASSC may occur at an unusually late age in patients receiving HU, possibly reflecting longer preservation of spleen perfusion and function secondary to early initiation of HU. Further studies are needed to better characterize the effects of HU on spleen perfusion/function and on the occurrence of ASSC in patients with SCD (ClinicalTrials.gov identifier: NCT02516579; European registry ENCEPP/SDPP/10565).
Banques de données
ClinicalTrials.gov
['NCT02516579']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
555-561Subventions
Organisme : Addmedica
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017;390(10091):311-323.
El Hoss S, Cochet S, Marin M, et al. Insights into determinants of spleen injury in sickle cell anemia. Blood Adv. 2019;3(15):2328-2336.
Brousse V, Buffet P, Rees D. The spleen and sickle cell disease: the sick(led) spleen. Br J Haematol. 2014;166(2):165-176.
Desselas E, Thuret I, Kaguelidou F, et al. Mortality in children with sickle cell disease in mainland France from 2000 to 2015. Haematologica. 2020;105(9):e440-e443.
Topley JM, Rogers DW, Stevens MC, Serjeant GR. Acute splenic sequestration and hypersplenism in the first five years in homozygous sickle cell disease. Arch Dis Child. 1981;56(10):765-769.
Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033-1048.
Emond AM, Collis R, Darvill D, Higgs DR, Maude GH, Serjeant GR. Acute splenic sequestration in homozygous sickle cell disease: natural history and management. J Pediatr. 1985;107(2):201-206.
Brousse V, Elie C, Benkerrou M, et al. Acute splenic sequestration crisis in sickle cell disease: cohort study of 190 paediatric patients. Br J Haematol. 2012;156(5):643-648.
Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011;377(9778):1663-1672.
de Montalembert M, Voskaridou E, Oevermann L, et al. Real-life experience with hydroxyurea in patients with sickle cell disease: results from the prospective ESCORT-HU cohort study. Am J Hematol. 2021;96(10):1223-1231.
Moll S, Orringer EP. Case report: splenomegaly and splenic sequestration in an adult with sickle cell anemia. Am J Med Sci. 1996;312(6):299-302.
Naymagon L, Pendurti G, Billett HH. Acute splenic sequestration crisis in adult sickle cell disease: a report of 16 cases. Hemoglobin. 2015;39(6):375-379.
Brown AK, Sleeper LA, Miller ST, Pegelow CH, Gill FM, Waclawiw MA. Reference values and hematologic changes from birth to 5 years in patients with sickle cell disease. Cooperative study of sickle cell disease. Arch Pediatr Adolesc Med. 1994;148(8):796-804.
Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood. 2005;106(7):2269-2275.
Nottage KA, Ware RE, Winter B, et al. Predictors of splenic function preservation in children with sickle cell anemia treated with hydroxyurea. Eur J Haematol. 2014;93(5):377-383.
Sachdev V, Sidenko S, Wu MD, et al. Skeletal and myocardial microvascular blood flow in hydroxycarbamide-treated patients with sickle cell disease. Br J Haematol. 2017;179(4):648-656.
Lobo CL, Pinto JF, Nascimento EM, Moura PG, Cardoso GP, Hankins JS. The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. Br J Haematol. 2013;161(6):852-860.
Tshilolo L, Tomlinson G, Williams TN, et al. Hydroxyurea for children with sickle cell anemia in sub-Saharan Africa. N Engl J Med. 2019;380(2):121-131.
Yee ME, Lai KW, Bakshi N, et al. Bloodstream infections in children with sickle cell disease: 2010-2019. Pediatrics. 2022;149(1):e2021051892.
Claster S, Vichinsky E. First report of reversal of organ dysfunction in sickle cell anemia by the use of hydroxyurea: splenic regeneration. Blood. 1996;88(6):1951-1953.
Nardo-Marino A, Glenthoj A, Brewin JN, et al. The significance of spleen size in children with sickle cell anemia. Am J Hematol. 2022;97(12):1520-1528.